Efficacy and Safety Study of NeuroStar TMS Therapy in Patients With Major Depressive Disorder With Postpartum Onset
An Open-Label Study to Evaluate the Efficacy and Safety of the Neuronetics NeuroStar TMS Therapy System in Patients With Major Depressive Disorder (MDD) With Postpartum Onset.
Sponsor: Neuronetics
Terminated
Slow enrollment
Listed as NCT01842542, this NA trial focuses on Depression, Postpartum and remains terminated or withdrawn. Sponsored by Neuronetics, it has been updated 7 times since 2013, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.
Status Flow
Change History
7 versions recorded-
Mar 2025 — Present [monthly]
Terminated NA
-
Sep 2024 — Mar 2025 [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Nov 2021 — Jul 2024 [monthly]
Terminated NA
Status: Completed → Terminated
-
Jan 2021 — Nov 2021 [monthly]
Completed NA
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed NA
-
Jan 2017 — Jun 2018 [monthly]
Completed NA
First recorded
Dec 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Neuronetics
For direct contact, visit the study record on ClinicalTrials.gov .